When bacteria develop antibiotic resistance, treatment with these medications becomes ineffective. Similarly, tumor cells can also change in such a way that renders them resistant to particular medications. This makes it vitally important for cancer patients and their doctors to determine as early as possible whether a specific therapy is working or not. A new blood test developed by researchers at the Technical University of Munich can predict drug resistance in patients with advanced prostate cancer.
A study led by Wistar scientists describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer-specific protein.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center.
Johns Hopkins Kimmel Cancer Center scientists report they have discovered a biochemical process that gives prostate cancer cells the almost unnatural ability to change their shape, squeeze into other organs and take root in other parts of the body. The scientists say their cell culture and mouse studies of the process, which involves a cancer-related protein called AIM1, suggest potential ways to intercept or reverse the ability of cancers to metastasize, or spread.
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
Both biophosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy. The results from a systematic review and meta-analysis are published in Annals of Internal Medicine.
Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50 percent of patient tumor samples. The discovery also identifies a new opportunity for targeted therapy.
Using open data from four previously conducted clinical trials, teams of international researchers designed mathematical models predicting the likelihood that a patient will discontinue docetaxel treatment due to adverse events.
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published Aug. 2, 2017, in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics Inc., USA, and colleagues.
CRG scientists identify important processes that create mutations that cause cancer by studying the genomes of more than 1,000 tumors. Many mutations in human cancers are caused by mistakes made by a repair mechanism or 'DNA spellchecker' rather than the actual damage to DNA caused by the environment. Sunlight and alcohol consumption increase the rate at which this happens, resulting in more mutations in the most important parts of our genomes.